参考文献/References:
[1] Bar-Or D,Winkler JV,Vanbenthuysen K,et al.Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin Ⅰ[J].Am Heart J,2001,141(6):985-991. DOI:10.1067/mhj.2001.114800.
[2] Garrett Q,Milthorpe BK.Human serum albumin adsorption on hydrogel contact lenses in vitro[J].Invest Ophthalmol Vis Sci,1996,37(13):2594-2602.
[3] Lehman-Mckeeman LD. Chapter 1-Biochemical and molecular basis of toxicity//Haschek and Rousseaux's Handbook of Toxicologic Pathology[M]. New Jersey:Elsevier Inc,2013:15-38.
[4] Sankaranarayanan S,de la Llera-Moya M,Drazul-Schrader D,et al.Serum albumin acts as a shuttle to enhance cholesterol efflux from cells[J].J Lipid Res,2013,54(3):671-676.DOI:10.1194/jlr.M031336.
[5] van der Vusse GJ. Albumin as fatty acid transporter[J].Drug Metab Pharmacokinet,2009,24(4):300-307.
[6] Laurie SH. Transport and storage of metals[J].J Inherit Metab Dis,1983,6(Suppl 1):9-14.
[7] Bal W,Sokoowska M,Kurowska E,et al.Binding of transition metal ions to albumin: sites, affinities and rates[J].Biochim Biophys Acta,2013,1830(12):5444-5455.DOI:10.1016/j.bbagen.2013.06.018.
[8] Sokoowska M,Wszelaka-Rylik M,Poznański J,et al.Spectroscopic and thermodynamic determination of three distinct binding sites for Co(II)ions in human serum albumin[J].J Inorg Biochem,2009,103(7):1005-1013. DOI:10.1016/j.jinorgbio.2009.04.011.
[9] Mothes E,Faller P.Evidence that the principal CoII-binding site in human serum albumin is not at the N-terminus: implication on the albumin cobalt binding test for detecting myocardial ischemia[J].Biochemistry,2007,46(8):2267-2274.
[10] Gutierrez-Correa J,Stoppani AO.Inactivation of yeast glutathione reductase by Fenton systems: effect of metal chelators, catecholamines and thiol compounds[J].Free Radic Res,1997,27(6):543-555.
[11] Borderie D,Allanore Y,Meune C,et al.High ischemia-modified albumin concentration reflects oxidative stress but not myocardial involvement in systemic sclerosis[J].Clin Chem,2004,50(11):2190-2193.DOI:10.1373/clinchem.2004.034371.
[12] Chawla R,Goyal N,Calton R,et al.Ischemia modified albumin: a novel marker for acute coronary syndrome[J].Indian J Clin Biochem,2006,21(1):77-82.DOI:10.1007/BF02913070.
[13] Dawie J,Chawla R,Worku Y,et al.Diagnosis of ischemic heart disease using CK-MB, troponin-Ⅰ and ischemia modified albumin[J].Ethiop Med J,2011,49(1):25-33.
[14] Guven S,Kart C,Guvendag Guven ES,et al.Is the measurement of serum ischemia-modified albumin the best test to diagnose ovarian torsion?[J].Gynecol Obstet Invest,2015,79(4):269-275.DOI:10.1159/000367787.
[15] Piwowar A,Knapik-Kordecka M,Warwas M.Ischemia-modified albumin level in type 2 diabetes mellitus-preliminary report[J].Dis Markers,2008,24(6):311-317.DOI:10.1155/2008/784313.
[16] Kaefer M,Piva SJ,De Carvalho JA,et al.Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus[J].Clin Biochem,2010,43(4-5):450-454. DOI:10.1016/j.clinbiochem.2009.11.018.
[17] Dahiya K,Aggarwal K,Seth S,et al.Type 2 diabetes mellitus without vascular complications and ischemia modified albumin[J].Clin Lab,2010,56(5-6):187-190.
[18] Dayanand CD, Vegi PK, Lakshmaiah V, et al. Association of ischemia modified albumin in terms of hypoxic risk with carbonylated protein, glycosylated hemoglobin and plasma insulin in type 2 diabetes mellitus[J]. Int J Biotechnol Biochem, 2013,9(3):275-284.
[19] Libby P,Ridker PM.Novel inflammatory markers of coronary risk: theory versus practice[J].Circulation,1999,100(11):1148-1150.DOI:10.1161/01.cir.100.11.1148.
[20] Ross R.Atherosclerosis--an inflammatory disease[J].N Engl J Med,1999,340(2):115-126. DOI:10.1056/NEJM199901143400207.
[21] Mohr FW,Morice MC,Kappetein AP,et al.Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial[J].Lancet,2013,381(9867):629-638.DOI:10.1016/S0140-6736(13)60141-5.
[22] Turan T,Akyüz AR,Sahin S,et al.Association between the plasma levels of IMA and coronary atherosclerotic plaque burden and ischemic burden in early phase of non-ST-segment-elevation acute coronary syndromes[J].Eur Rev Med Pharmacol Sci,2017,21(3):576-583.
[23] Koç F,Erdem S,Altunka F,et al.Ischemia-modified albumin and total antioxidant status in patients with slow coronary flow: a pilot observational study[J].Anadolu Kardiyol Derg,2011,11(7):582-587.DOI:10.5152/akd.2011.159.
[24] American Diabetes Association. Diagnosis and classification of diabetes mellitus[J].Diabetes Care,2012,35( Suppl 1):S64-S71.DOI:10.2337/dc12-s064.
[25] Libby P.Molecular bases of the acute coronary syndromes[J].Circulation,1995,91(11):2844-2850.DOI:10.1161/01.cir.91.11.2844.
[26] Mehmetogˇlu I,Kurban S,Yerlikaya FH,et al.Obesity is an independent determinant of ischemia-modified albumin[J].Obes Facts,2012,5(5):700-709. DOI:10.1159/000343954.
[27] Chawla R,Loomba R,Guru D,et al.Ischemia modified albumin(IMA)- a marker of glycaemic control and vascular complications in type 2 diabetes mellitus[J].J Clin Diagn Res,2016,10(3):BC13-BC16.DOI:10.7860/JCDR/2016/15282.7432.
[28] Turk A,Nuhoglu I,Mentese A,et al.The relationship between diabetic retinopathy and serum levels of ischemia-modified albumin and malondialdehyde[J].Retina,2011,31(3):602-608.DOI:10.1097/IAE.0b013e3181ed8cd1.
[29] Gulpamuk B,Tekin K,Sonmez K,et al.The significance of thiol/disulfide homeostasis and ischemia-modified albumin levelsto assess the oxidative stress in patients with different stages of diabetes mellitus[J].Scand J Clin Lab Invest,2018,78(1-2):136-142.DOI:10.1080/00365513.2017.1422540.
[30] Kirboga K,Ozec AV,Kosker M,et al.The association between diabetic retinopathy and levels of ischemia-modified albumin, total thiol, total antioxidant capacity, and total oxidative stress in serum and aqueous humor[J].J Ophthalmol,2014,2014:820853.DOI:10.1155/2014/820853.
[31] Gulpamuk B,Tekin K,Sonmez K,et al.The significance of thiol/disulfide homeostasis and ischemia-modified albumin levels to assess the oxidative stress in patients with different stages of diabetes mellitus[J].Scand J Clin Lab Invest,2018,78(1-2):136-142.DOI:10.1080/00365513.2017.1422540.
[32] Bilgi M,Keser A,Katlandur H,et al.Evaluation of the relationship between microalbuminuria and urine ischemia-modified albumin levels in patients with diabetic nephropathy[J].J Clin Lab Anal,2017,31(3).DOI:10.1002/jcla.22058.
[33] Ukinc K,Eminagaoglu S,Ersoz HO,et al.A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin[J].Endocrine,2009,36(3):425-432. DOI:10.1007/s12020-009-9236-5.
[34] Ahn JH,Choi SC,Lee WG,et al.The usefulness of albumin-adjusted ischemia-modified albumin index as earlydetecting marker for ischemic stroke[J].Neurol Sci,2011,32(1):133-138.DOI:10.1007/s10072-010-0457-4.
[35] 孙华,郭玉珊,翟羽佳,等.缺血修饰性白蛋白指数与2型糖尿病合并早期肾病的关系[J].中国老年学, 2014,33(19):5399-5400.
[36] Ahmad A,Manjrekar P,Yadav C,et al.Evaluation of ischemia-modified albumin, malondialdehyde, and advanced oxidative protein products as markers of vascular injury in diabetic nephropathy[J].Biomark Insights,2016,11:63-68.DOI:10.4137/BMI.S39053.
[37] Miric DJ,Kisic BM,Filipovic-Danic S,et al.Xanthine oxidase activity in type 2 diabetes mellitus patients with and without diabetic peripheral neuropathy[J].J Diabetes Res,2016,2016:4370490. DOI:10.1155/2016/4370490.
[38] Muhtarogˇlu S,Barlak Keti D, Ünlühizarci K.Investigation of ischemia-modified albumin levels and some atherosclerosis-related serum parameters in patients with diabetic foot[J].Turk J Med Sci,2016,46(1):126-132.DOI:10.3906/sag-1406-38.
[39] Cakmak T,Metin S,Yaman H,et al.The effect of hyperbaric oxygen therapy on ischemia-modified albumin levels in people with diabetes with foot ulcers[J].Undersea Hyperb Med,2014,41(4):277-281.
[40] Beetham R,Monk C,Keating L,et al.Effects of storage at -20 degrees C on ischaemia-modified albumin results[J].Ann Clin Biochem,2006,43(Pt 6):500-502.DOI:10.1258/000456306778904669.
相似文献/References:
[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(05):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(05):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[4]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制
——2014年美国糖尿病协会“杰出科学成就奖”
演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[5]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[6]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[7]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[8]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[9]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[10]吕丹 李晓思 陈树春 王泽普.Betatrophin:糖尿病再生治疗的新希望[J].国际内分泌代谢杂志,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
Lyu Dan*,Li Xiaosi,Chen Shuchun,et al.Betatrophin:new hope for regeneration therapy of diabetes[J].International Journal of Endocrinology and Metabolism,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]